The DOI matches its Crossref record; 216 of the 218 references it cites were found in a registry or an index.
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
Open accessAbstract
The purpose of this article is to provide updated recommendations for the treatment of patients with stage IV non-small-cell lung cancer. A literature search identified relevant randomized trials published since 2002. The scope of the guideline was narrowed to chemotherapy and biologic therapy. An Update Committee reviewed the literature and made updated recommendations. One hundred sixty-two publications met the inclusion criteria. Recommendations were based on treatment strategies that improve overall survival. Treatments that improve only progression-free survival prompted scrutiny of toxicity and quality of life. For first-line therapy in patients with performance status of 0 or 1, a platinum-based two-drug combination of cytotoxic drugs is recommended. Nonplatinum cytotoxic doublets are acceptable for patients with contraindications to platinum therapy. For patients with performance status of 2, a single cytotoxic drug is sufficient. Stop first-line cytotoxic chemotherapy at disease progression or after four cycles in patients who are not responding to treatment. Stop two-drug cytotoxic chemotherapy at six cycles even in patients who are responding to therapy. The first-line use of gefitinib may be recommended for patients with known epidermal growth factor receptor (EGFR) mutation; for negative or unknown EGFR mutation status, cytotoxic chemotherapy is preferred. Bevacizumab is recommended with carboplatin-paclitaxel, except for patients with certain clinical characteristics. Cetuximab is recommended with cisplatin-vinorelbine for patients with EGFR-positive tumors by immunohistochemistry. Docetaxel, erlotinib, gefitinib, or pemetrexed is recommended as second-line therapy. Erlotinib is recommended as third-line therapy for patients who have not received prior erlotinib or gefitinib. Data are insufficient to recommend the routine third-line use of cytotoxic drugs. Data are insufficient to recommend routine use of molecular markers to select chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, multiple trials did not identify age as a pretreatment risk factor for either tolerance or response to treatment with cytotoxic therapy.1”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Self-citationErlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationCOMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655
Research works printed but not linked: 7
- 10.1200/jco.2002.20.5.1335 · DOI
- Lynch TJ, Presented at the 12th World Conference on Lung Cancer
- Lord RV, 2002, Clin Cancer Res, 8, 2286
- Mihaylova Z, 2007, J BUON, 12, 105
- Langer CJ, 2004, Oncology, 18, 17
- Brose MS, 2002, Cancer Res, 62, 6997
- Suzuki Y, 1990, Oncogene, 5, 1037
Cited by
Sorted by citations
Items 901–911 of 911
Satıcı, C., & Yılmaz, U. (2023) · Springer eBooks · doi:10.1007/978-3-031-22483-6_67-1
GENETICALLY ENGINEERED BIOLOGICAL THERAPY IN ONCOLOGY (literature review)
Mamedova, S. (2023) · Clinical Medicine and Pharmacology · doi:10.12737/2409-3750-2023-9-3-26-32
Sarkar, U. N., Alam, S., Hoque, S., Sarker, N. K., Mahmud, T., & Hossain, S. (2025) · International Journal of Clinical Oncology and Cancer Research · doi:10.11648/j.ijcocr.20251002.12
Biology and Treatment Options for Non-small Cell Lung Cancer
Kish, K. (2025) · Springer eBooks · doi:10.1007/978-3-032-02200-4_15
Fortgeschrittenes nichtkleinzelliges Lungenkarzinom
Schütte, W., Nagel, S., Haak, G., & Steinert, M. (2012) · Der Pneumologe · doi:10.1007/s10405-011-0501-y
Gollner, S., Ivanenko, V. N., & Arbizu, P. M. (2008) · INFM-OAR (INFN Catania) · doi:10.5281/zenodo.183746
Agarwal, A. A., Livingstone, A., Karikios, D. J., Stockler, M. R., Beale, P., & Morton, R. L. (2021) · Figshare · doi:10.6084/m9.figshare.16633242
Advances in Lung Cancer Management: Novel Approaches and the Road Ahead
Choudhary, F., Mustafa, M., Farooqui, M. R., Nizam, A., Abdin, M. Z., & Farooqi, H. (2026) · Clinical Cancer Drugs · doi:10.2174/012212697x412648260114111222
Wang, S., Liu, J., Nie, Q., Shi, R., Xu, N., He, Q., Ye, G., Liu, J., Hou, Q., 邓克学, et al. (2026) · MedComm · doi:10.1002/mco2.71032
Monoclonal antibodies associated IgA nephropathy or other nephropathies
Miedziaszczyk, M., Kosiorowski, G., Kubasik, J., Grabowski, T., Szałek, E., Szeto, C. C., & Idasiak‐Piechocka, I. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1891000
Tumor hypoxia and hypoxic markers in non-small cell lung cancer
Eilertsen, M. (2014) · NORA - Norwegian Open Research Archives
Metadata
- Authors
- Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., Nordquist, L., Pfister, D. G., Piantadosi, S., Schiller, J. H., Smith, R., Smith, T. J., Strawn, J. R., Trent, D., & Giaccone, G.
- Affiliations
- American Society of Clinical Oncology (US)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2009-12-20
- Volume
- 27
- Issue
- 36
- Pages
- 6251-6266
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC2793036
- OpenAlex
- W2119366998
- Cited by
- 915
- References
- 218
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 12 · 2021: 25 · 2020: 21 · 2019: 33 · 2018: 38 · 2017: 38 · 2016: 67 · 2015: 89 · 2014: 111 · 2013: 128 · 2012: 119
- FWCI
- 90.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- stage IV non-small cell lung cancer, chemotherapy, first-line therapy, second-line therapy, third-line therapy, gefitinib, erlotinib, bevacizumab, carboplatin-paclitaxel, cetuximab, docetaxel, EGFR mutation, platinum-based doublets, overall survival, progression-free survival, treatment toxicity
- MeSH terms
- Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Staging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
